Lower Cerebrospinal Fluid Concentration of Brain-Derived Neurotrophic Factor Predicts Progression from Mild Cognitive Impairment to Alzheimer's Disease
Carregando...
Citações na Scopus
54
Tipo de produção
article
Data de publicação
2015
Título da Revista
ISSN da Revista
Título do Volume
Editora
HUMANA PRESS INC
Autores
DINIZ, Breno Satler
TEIXEIRA, Antonio Lucio
ROCHA, Natalia Pessoa
Citação
NEUROMOLECULAR MEDICINE, v.17, n.3, p.326-332, 2015
Resumo
There is little information on the dynamics of BDNF in the CSF in the continuum between healthy aging, MCI and AD. We included 128 older adults (77 with amnestic MCI, 26 with AD and 25 healthy controls). CSF BDNF level was measured by ELISA assay, and AD biomarkers (A beta(42), T-Tau and P-Tau(181)) were measured using a Luminex xMAP assay. CSF BDNF levels were significantly reduced in AD subjects compared to MCI and healthy controls (p = 0.009). Logistic regression models showed that lower CSF BDNF levels (p = 0.008), lower CSF A beta(42) (p = 0.005) and lower MMSE scores (p = 0.007) are significantly associated with progression from MCI to AD. The present study adds strong evidence of the involvement of BDNF in the pathophysiology of neurodegenerative changes in AD. Interventions aiming to restore central neurotrophic support may represent future therapeutic targets to prevent or delay the progression from MCI to AD.
Palavras-chave
Alzheimer's disease, Mild cognitive impairment, Brain-derived neurotrophic factor, Cerebrospinal fluid, Biomarkers, Pathophysiology
Referências
- Alvarez XA, 2011, EUR J NEUROL, V18, P59, DOI 10.1111/j.1468-1331.2010.03092.x
- Angelucci F, 2010, CURR ALZHEIMER RES, V7, P15
- Blasko I, 2006, DEMENT GERIATR COGN, V21, P9, DOI 10.1159/000089137
- Brunoni AR, 2008, INT J NEUROPSYCHOPH, V11, P1169, DOI 10.1017/S1461145708009309
- Christensen R, 2008, EXP NEUROL, V210, P164, DOI 10.1016/j.expneurol.2007.10.009
- Clement F, 2010, BIOL PSYCHIAT, V68, P894, DOI 10.1016/j.biopsych.2010.02.004
- Covaceuszach S, 2009, CURR ALZHEIMER RES, V6, P158
- de Sousa RT, 2011, NEUROSCI LETT, V494, P54, DOI 10.1016/j.neulet.2011.02.054
- Diniz BS, 2010, WORLD J BIOL PSYCHIA, V11, P550, DOI 10.3109/15622970903544620
- Diniz BS, 2011, NEUROMOL MED, V13, P217, DOI 10.1007/s12017-011-8154-x
- Diniz BS, 2014, J GERONTOL B-PSYCHOL, V69, P845, DOI 10.1093/geronb/gbu096
- Diniz BS, 2015, MOL PSYCHIATR, V20, P594, DOI 10.1038/mp.2014.76
- Diniz BS, 2014, J PSYCHIATR RES, V49, P96, DOI 10.1016/j.jpsychires.2013.11.004
- Douillard-Guilloux G, 2013, AM J GERIAT PSYCHIAT, V21, P450, DOI 10.1016/j.jagp.2013.01.040
- Faria MC, 2014, J PSYCHIATR RES, V53, P166, DOI 10.1016/j.jpsychires.2014.01.019
- Forlenza OV, 2010, WORLD J BIOL PSYCHIA, V11, P774, DOI 10.3109/15622971003797241
- Forlenza OV, 2011, BRIT J PSYCHIAT, V198, P351, DOI 10.1192/bjp.bp.110.080044
- Forlenza OV, 2010, REV BRAS PSIQUIATR, V32, P216, DOI 10.1590/S1516-44462010005000002
- Huijbers W, 2015, BRAIN, V138, P1023, DOI 10.1093/brain/awv007
- Laske C, 2007, J PSYCHIATR RES, V41, P387, DOI 10.1016/j.jpsychires.2006.01.014
- Li G, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005424
- MCKHANN G, 1984, NEUROLOGY, V34, P939
- Miller SL, 2008, J NEUROL NEUROSUR PS, V79, P630, DOI 10.1136/jnnp.2007.124149
- Nagahara AH, 2009, NAT MED, V15, P331, DOI 10.1038/nm.1912
- Peng SY, 2005, J NEUROCHEM, V93, P1412, DOI 10.1111/j.1471-4159.2005.03135.x
- Petersen RC, 2001, ARCH NEUROL-CHICAGO, V58, P1985, DOI 10.1001/archneur.58.12.1985
- PHILLIPS HS, 1991, NEURON, V7, P695, DOI 10.1016/0896-6273(91)90273-3
- Rockenstein E, 2011, J NEUROSCI RES, V89, P1812, DOI 10.1002/jnr.22712
- Shimada H, 2014, FRONT AGING NEUROSCI, V6, DOI 10.3389/fnagi.2014.00069
- Sibille Etienne, 2013, Dialogues Clin Neurosci, V15, P53
- Teixeira AL, 2010, BIOMARK MED, V4, P871, DOI [10.2217/bmm.10.111, 10.2217/BMM.10.111]
- Weinstein G, 2014, JAMA NEUROL, V71, P55, DOI 10.1001/jamaneurol.2013.4781
- Yu H, 2008, J CLIN PSYCHIAT, V69, P1104